

Abstract

The present invention provides compounds having kinase inhibitory activity. Specifically, the present invention provides compounds having a structure represented by the following formula (II). The compound of the present invention has good inhibitory activity for a variety of kinases (e.g. ALK, AXL, EGFR, and FLT3), and therefore can be used for preparing a pharmaceutical composition for treating kinase activity-related diseases (e.g. acute myeloid leukemia, etc.).

